摘要
目的:探讨氨磺必利和齐拉西酮治疗女性精神分裂症的临床疗效。方法:择取2017年4月至2019年6月期间我院收治的76例女性精神分裂症患者参与研究,根据患者不同治疗方法进行分组,包括氨磺必利组38例和齐拉西酮组38例。两组患者分别给药氨磺必利和齐拉西酮进行8周治疗。比较两组患者临床疗效、阳性症状与阴性症状量表(PANSS)及不良反应情况。结果:氨磺必利组患者临床疗效94.74%,齐拉西酮组临床疗效为89.47%,数据输入统计学软件进行计算,结果显示无显著差异(P>0.05);两组患者PANSS评分数据输入统计学软件进行计算,结果显示无显著差异(P>0.05);氨磺必利组患者不良反应发生率15.79%,齐拉西酮组不良反应发生39.47%,数据输入统计学软件进行计算,结果显示差异显著(P<0.05)。结论:氨磺必利以及齐拉西酮对女性精神分裂症患者均具有良好的治疗效果,但是氨磺必利治疗安全性相对更高,因此其在临床中具有更高的推广价值。
Objective:To explore the clinical effect of sulfabilide and ziprasidone in the treatment of female schizophrenia.Method:76 female schizophrenics admitted to our hospital from April 2017 to June 2019 were selected to participate in the study.According to the different treatment methods of the patients,they were divided into three groups,including 38 cases in the sulfapiride group and 38 cases in the ziprasidone group.The patients in the two groups were treated with sulpiride and ziprasidone for 8 weeks.The clinical efficacy,PANSS and adverse reactions were compared between the two groups.Result:There was no significant difference between the two groups(P>0.05);the incidence of adverse reactions was 15.79%in the sulfapiride group and 89.47%in the ziprasidone group The response rate was 39.47%,and the difference was significant(P<0.05).Conclusion:Ambroxide and ziprasidone have good therapeutic effect on female schizophrenics,but the safety of ambroxide is relatively higher,so it has a higher promotion value in clinical.
出处
《黑龙江医药》
CAS
2020年第5期1093-1095,共3页
Heilongjiang Medicine journal
